The role of human IL-17 immunity in fungal disease

Current Fungal Infection Reports

Volumn 7, Issue 2, 2013, Pages 132-137

  Maródi, László ^a   Cypowyj, Sophie ^b   Casanova, Jean Laurent ^b,c,d   Puel, Anne ^b,c,d  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b ROCKEFELLER UNIVERSITY   (United States)

^c IMAGINE INSTITUTE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Candida; Mucocutaneous candidiasis; Primary immunodeficiency disorders; Th17 cells

Indexed keywords

INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; NEUTRALIZING ANTIBODY; PROTEIN KINASE TYK2; STAT1 PROTEIN; STAT3 PROTEIN;

ARTICLE; AUTOIMMUNE DISEASE; CANDIDA; CELL FUNCTION; CELLULAR IMMUNITY; DISEASE PREDISPOSITION; GAIN OF FUNCTION MUTATION; HELPER CELL; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MOLECULAR PATHOLOGY; MUCOCUTANEOUS CANDIDIASIS; PROTEIN DEFICIENCY;

EID: 84882839207     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-013-0131-4     Document Type: Article

References (58)

1. Casanova J-L, Abel L. Inborn errors of immunity to infection: the rule rather than the exception. J Exp Med. 2005;202:197-201.
2. • Fischer A. Human primary immunodeficiency diseases. Immunity 2007;27:835-45. A comprehensive review on novel primary immunodeficiencies.
3. • Casanova J-L, Abel L. Primary immunodeficiencies: a field in its infancy. Science 2007;317:617-9. A clear and concised summary of the concept of primary immunodeficiencies as an emerging field of immunology and medicine.
4. • Maródi L, Notarangelo LD. Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol 2007;7:851-61. A comprehensive review on several novel primary immunodeficiencies.
5. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2):S182-94.
6. Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8mutations. N Engl J Med. 2009;36:2046-55.
7. Cypowyj S, Picard C, Maródi L, et al. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol. 2012;42(9):2246-54.
8. Puel A, Cypowyj S, Maródi L, et al. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol. 2012;12(6):616-22.
9. • Maródi L, Cypowyj S, Tóth B, et al. Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol. 2012;130(5):1019-27. A comprehensive review on the molecular basis of susceptibility to Candida and Staphylococci in humans.
10. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 2007;19(3):281-6.
11. Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Cytokine Growth Factor Rev. 2007;19(6):400-8.
12. McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity. 2008;28(4):445-53.
13. Marks BR, Nowyhed HN, Choi JY, et al. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat Immunol. 2009;10(10):1125-32.
14. Zhou L, Littman DR. Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol. 2009;21(2):146-52.
15. Hirahara K, Ghoreschi K, Laurence A, et al. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev. 2010;21(6):425-34.
16. May MJ. IL-17R signaling: new players get in on the Act1. Nat Immunol. 2011;12(9):813-5.
17. Sallusto F, Zielinski CE, Lanzavecchia A. Human Th17 subsets. Eur J Immunol. 2012;42:2215-20.
18. Ness-Schwickerath KJ, Jin C, Morita CT. Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells. J Immunol. 2010;184(12):7268-80.
19. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479-89.
20. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011;23(5):613-9.
21. Hardison SE, Brown GD. C-type lectin receptors orchestrate antifungal immunity. Nat Immunol. 2012;13(9):817-22.
22. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12:220-9.
23. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36:1-53.
24. Maródi L. Local and systemic host defense mechanisms against Candida: immunopathology of candidal infections. Pediatr Infect Dis J. 1997;16:795-801.
25. Maródi L, Johnston Jr RB. Invasive Candida species disease in infants and children: occurrence, risk factors, management, and innate host defense mechanisms. Curr Opin Pediatr. 2007;19:693-7.
26. Maródi L, Leijh PC, van Furth R. Characteristics and functional capacities of human cord blood granulocytes and monocytes. Pediatr Res. 1984;18:1127-31.
27. Husebye ES, Perheentupa J, Rautemaa R, Kampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med. 2009;265:514-29.
28. Mc Cormack O, Timlin M, McGowan A, Healy ML, Ravi N, Reynolds JV. Management of squamous cell cancer of the oesophagus in a patient with a polyglandularendocrinopathy (APECED) and achalasia. J Gastro Intest Surg. 2012;16(10):1963-6.
29. Böckle BC, Wilhelm M, Müller H, Götsch C, Sepp NT. Oral mucous squamous cell carcinoma-an anticipated consequence of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J Am Acad Dermatol. 2010;62(5):864-8.
30. • Puel A, Döffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, et al. Autoantibodies against IL-17A, IL-17 F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010;207:291-7. Refs 30 and 31 are companion papers describing the presence of autoantibobies against IL-17A, IL-17 F and IL-22 inpatients with APECED suggesting a specific role of these cytokines in the susceptipility of patients to Candida.
31. • Kisand K, Bøe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010;207:299-308. Refs 30 and 31 are companion papers describing the presence of autoantibobies against IL-17A, IL-17 F and IL-22 inpatients with APECED suggesting a specific role of these cytokines in the susceptipility of patients to Candida.
32. Kisand K, Lilic D, Casanova JL, Peterson P, Meager A, Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol. 2011;41:1517-27.
33. Tóth B, Wolff AS, Halász Z, Tar A, Szüts P, Ilyés I, et al. Novel sequence variation of AIRE and detection of interferon-omega antibodies in early infancy. Clin Endocrinol (Oxf). 2010;72:641-7.
34. + T helper cell differentiation. Nat Rev Immunol. 2011;11:239-50.
35. • Casanova J-L, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 2012;36:515-28. A comprehensive review on various mutations of JAKs and STATs causing various clinical phenotypes.
36. • Boisson-Dupuis S, Kong XF, Okada S, Cypowyj S, Puel A, Abel L, et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr Opin Immunol 2012;(4):364-78. This is a comprehensive description of disease-causing mutations in STAT1.
37. • Minegishi Y, Saito M, Tsuchiya A, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007;448:1058-62. Refs. 37 and 38 are companion papers describing the genetic etiology of autosomal dominant and sporadic hyper-IgE syndrome.
38. • Holland SM, De Leo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007;357:1608-19. Refs. 37 and 38 are companion papers describing the genetic etiology of autosomal dominant and sporadic hyper-IgE syndrome.
39. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205:1551-7.
40. + CD4 T cell depletion.
41. Jiao H, Tóth B, Erdos M, Fransson I, Rákóczi E, Balogh I, et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol. 2008;46:202-6.
42. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med. 2008;205:1543-50.
43. + CD4 T cell depletion in patients with autosomal dominant and sporadic hyper-IgE syndrome.
44. Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine. 2012;91(4):1-19.
45. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006;25:745-55.
46. • Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, Kreins AY, Grant AV, Abel L, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 2012;160:1055-7. The authors report here the second Tyk2 deficient patient with phenotypic expression different from that observed in the first patient (Minegishi et al., Immunity 2006;25:745-55).
47. Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, Feinberg J, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol. 2006;18(6):347-61.
48. Al-Muhsen S, Casanova JL. The genetic heterogeneity of Mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol. 2008;122:1043-51.
49. de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore). 2010;89:381-402.
50. • Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-8. This is the first report on AR IL-17RA and AD IL-17F deficiencies predisposing patients to chronic mucocutaneous candidiasis disease. The authors clearly demonstrate an essential role of humanIL-17A and/or IL-17 F in host defense against Candida on mucocutaneous surfaces.
51. • Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011;208:1635-48. This is one of the very first reports on chronic mucocutaneous candidiasis disease caused by dominant mutations in STAT1 in a series of 47 patients. The authors provide mechanistic data suggesting that the mutant alleles are gain-of function due to gain of nuclear phosphorylation of STAT1.
52. • van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011;365:54-61. This is one of the very first reports describing dominant mutations in STAT1 causing chronic mucocutaneous candidiasis disease in a series of 14 patients.
53. • Tóth B, Méhes L, Taskó S, Szalai Z, Tulassay, Cypowyj S, et al. Herpes in STAT1mutation. The Lancet 2012;379:2500. This study is the first description of two related patients with a STAT1coiled coil domain gain-of-function mutation associated with recurrent herpes virus disease in addition to chronic mucocutaneous candidiasis.
54. Smeekens SP, Plantinga TS, van de Veerdonk FL, et al. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS One. 2011;6(12):e29248.
55. Hori T, Ohnishi H, Teramoto T, et al. Autosomal-dominant chronic mucocutaneous candidiasis with STAT1-mutation can be complicated with chronic active hepatitis and hypothyroidism. J Clin Immunol. 2012;32(6):1213-20.
56. Takezaki S, Yamada M, Kato M, et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol. 2012;189(3):1521-6.
57. Tsumura M, Okada S, Sakai H, Yasunaga S, Ohtsubo M, Murata T, et al. Dominant-negative STAT1 SH2 domain mutations in unrelated patients with Mendelian susceptibility to mycobacterial disease. Hum Mutat. 2012;33(9):1377-87.
58. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol. 2011;2:54. doi: 10.3389/fimmu.